⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13558623 | 0.81 | PNMT (0.54) | — | |
| SCHEMBL11088 | 0.80 | — | — | |
| Iodide SCHEMBL30536887 | 0.79 | PNMT (0.69) | — | |
| Hydrochloric Acid SCHEMBL1427992 | 0.79 | PNMT (0.69) | — | |
| SCHEMBL6511764 | 0.77 | PNMT (0.61) | — | |
| Hydrochloric Acid SCHEMBL366688 | 0.75 | PNMT (0.95) | — | |
| Bromide SCHEMBL28557676 | 0.75 | PNMT (0.95) | — | |
| Hydrochloric Acid SCHEMBL5317536 | 0.74 | PNMT (0.91) | — | |
| SCHEMBL3581219 | 0.74 | PNMT (0.76) | — | |
| SCHEMBL5186329 | 0.72 | PNMT (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122225-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025072437-A1 | HETEROARYL COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ALPHINA THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2023137297-A3 | 5,6-DIHYDRO-4H-THIENO[2,3-C]PYRROLE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023137297-A2 | 5,6-DIHYDRO-4H-THIENO[2,3-C]PYRROLE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137297-A2 | 5,6-DIHYDRO-4H-THIENO[2,3-C]PYRROLE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023274280-A1 | CRYSTAL FORM OF BIPHENYL DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR | 上海翰森生物医药科技有限公司 | 2023-01-05 | — | — | WO | disclosed |
| WO-2022121914-A1 | OXO-NITROGEN RING DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2022-06-16 | — | — | WO | disclosed |
| WO-2021136354-A1 | BIPHENYL DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2021-07-08 | — | — | WO | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| CN-102056894-A | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORP | 2011-05-11 | — | — | CN | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |